CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. CorMedix Inc. (NASDAQ:CRMD) stands sixth among them.

CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company focused on therapies to prevent and treat life-threatening diseases, with DefenCath, an antimicrobial catheter lock for dialysis patients, as its lead commercial product.

In August 2025, CorMedix Inc. (NASDAQ:CRMD) announced the acquisition of Melinta Therapeutics, a commercial-stage company with seven marketed hospital- and clinic-focused infectious disease products, including REZZAYO™ for candidemia and invasive candidiasis. The acquisition, expected to close by September 1, will diversify CRMD’s portfolio, expand its acute hospital care presence, and enhance R&D and commercial capabilities. The combined company is projected to generate $305–$335 million in 2025 revenue, with annual synergies of $35–$45 million, and is expected to be accretive to earnings with double-digit EPS growth in 2026. This strategic move also highlights how CRMD, often categorized among overlooked stocks, is positioning itself for broader recognition in the healthcare space.

CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio

CorMedix Inc. (NASDAQ:CRMD) continues to see strong growth in DefenCath sales, supporting its market position. The corporation faces some legal challenges from shareholder lawsuits alleging misleading statements, contributing to stock volatility.

While we acknowledge the risk and potential of CRMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRMD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.